Breast Neoplasms  >>  carotuximab IV (ENV-105)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carotuximab IV (ENV-105) / Kairos Pharma
NCT01326481: Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1b
19
US
TRC105, carotuximab, Capecitabine, xeloda
Tracon Pharmaceuticals Inc., Roswell Park Cancer Institute, United States Department of Defense
Metastatic Breast Cancer
09/14
12/14

Download Options